Market events
SELLAS (SLS) reports longer survival in its Phase 3 REGAL trial
SELLAS reported median survival of 24.0 versus 14.7 months in its Phase 3 REGAL trial. See who was studied, the FDA filing target and funding context.
Lead story · No. 055
Market events
SELLAS reported median survival of 24.0 versus 14.7 months in its Phase 3 REGAL trial. See who was studied, the FDA filing target and funding context.
Market events
Cue Biopharma fell from $14.10 to $2.83 on Nov. 17, with four volatility halts in the first half hour and most volume after 1 p.m. What it reported the night before, and what is unexplained.
Market events
Tronox fell about 21% on Nov. 17 after a media report said creditors had hired restructuring advisers. The company had filed nothing new. Its Q3 debt, liquidity and maturity disclosures, and what is unknown.
Market Analysis
A subsidiary's regional distributor deal with no stated value, 209.7 million shares traded against 15.0 million outstanding, and the share pools behind it.
Reading the session
Learn how gap up and gap down are calculated, how opening gaps differ from premarket changes, and why the reference price and timestamp matter.
Data study
A look at 671 US stock gap-ups of 20% or more from July 1 to October 2, 2026: when the 4:00 a.m.–8:00 p.m. ET high printed, split by gap size, price and how the day ended.
Research process
Research why a stock moved using company announcements, SEC filings, and a source-linked timeline. Separate confirmed events from explanations and unknowns.
Market status
Learn what a stock trading halt means, how to check official halt codes and resumption times, and how to distinguish a halt from inactive or delayed data.
Retrospective data built after the session from stored records, with links to the original sources. Not real-time, not investment advice and not a recommendation to buy or sell any security.